

## Drugs and Pharmaceuticals Industry Highlights

### Contents

Chapter	Page	Chapter	Page
<b>Feature</b>	<b>1</b>	– US congress considers new bill for generic drugs	
– Drug discovery and development: An Indian perspective		– Bayer to slash 6,100 jobs	
<b>News &amp; Views</b>		– Merck cuts anti-aids drug price	
<b>Indian</b>		– Climate change to hit the pharmaceutical industry	
<b>Industry News</b>	<b>5</b>	– Merck cuts price of once daily HIV drug	
– Pharma industry mixed reaction to budget		– Indonesia agrees to share flu virus sample with WHO	
– NPIL to invest \$50 mn in new facilities		<b>Healthcare News</b>	<b>19</b>
– Ranbaxy gets regulatory nod in Romania		– Health sector gets Rs. 15,291 crore in budget	
– Pharma sector sets for double digit growth		– India tops in childhood pneumonia cases	
– Domestic pharma firms perform well in third quarter		– Nutraceuticals market in India to grow	
– Alkem healths plan Rs 25 cr investment expansion		– Government focuses on polio eradication in union budget	
– Dishman forms Japanese jv		– 11 cases of polio detected this year	
– Ranbaxy bids for Merck generic unit		– Programme to fight flourosis	
– FDI flow declines in pharma sector		– World population will reach 9.2 billion by 2050	
– Glenmark's Argentina subsidiary gives positive growth		– Neurological disorders affect millions globally: WHO report	
<b>Regulatory News</b>	<b>8</b>	– Canada & Gates foundation launches new HIV vaccine R&D partnership	
– Bulk drugs price fixation		– WHO reports some promising results on avian influenza vaccines	
– Ceiling price fixation		<b>Product News</b>	<b>25</b>
– Budget proposals announced for 2007-08		– Cipla enters agreement with DNDi for anti-	
<b>Global News</b>	<b>16</b>		

- malarial drug
- Ranbaxy outlicenses NCE to US firm
- Ethypharm in licensing deal with Shantha Biotechnics
- Glaxo new cancer drug gets USFDA approval
- Ranbaxy targets US for \$2b sales from generic brands
- Ranbaxy arm gets nod for 20 products
- DCGI approves Bentley's nasulin trial in India
- Strides Arcolab gets US FDA nod for ARV fixed dose combination
- Merck & Co's new HIV treatment shows promise in phase III
- Sanofi-Aventis to launch fixed dose anti-malarial with private partnership
- Indian drug cos focus on new molecules

### **R&D News** 29

- Glanmark in pact with Dyax for research
- GVK Bio enters into JV with INC research
- Novozymes to set up R&D centre in Bangalore
- Nicholas Piramal to invest \$50m in contract manufacturing business
- R&D proposals signed at Bio-Asia 2007
- Regulatory delay hit clinical research firms

### **Biotechnology** 32

- Indian biotech sector achieves 35% growth
- Biocon subsidiary enters R&D pact with Bristol Myers
- Biocon launches nephrology division
- Biotech firms mixed reactions on budget
- Biocon to invest rs. 1000 cr. in Andhra Pradesh
- Geovax's HIV vaccine shows promise in phase I trials
- First recombinant polyclonal antibody enter clinical trial
- US promotes biogenerics introduction

### **Patents** 35

- Recent Indian patents in the field of drugs &

- pharmaceuticals
- Govt. unlikely to accept Mashelkar view on widening patent scope
- Indian laws does not comply with IPR: Novartis
- Rejecting patents on chemical derivatives inhibits innovation: Novartis
- EU, US shows concern over public health
- Indian patents act does not violate trips, govt tells HC
- Ranbaxy suit in US for delay in launch of generic drug
- Pfizer challenges Ranbaxy against Caduet
- Pharma claims 10.4% of all worldwide patent application
- US patent office rejects Genetech's Cabilly II patent
- Pfizer sues Ranbaxy on patent infringement

### **Parliament News**

#### **Lok Sabha** 51

- Central drug authority
- Herbal drug for diabetics
- Prevention of bird flu
- AIDS vaccine
- Polio cases
- Aswagandha for treatment of HIV/AIDS
- Treatment of HIV/AIDS

#### **Rajya Sabha** 54

- Soya yoghurt for diabetes .
- Phase III of AIDS control
- New medicines for HIV
- Measures taken for surveillance of leprosy
- National plan for advanced TB control programme
- Stem cell research
- Grape juice for weight loss
- Clinical trials of medicines

Views expressed in the journal are those of the authors and the Editorial Board/Publisher takes no responsibility for the same. We are a secondary abstracting service and the veracity of information is of the source quoted and not our primary responsibility.

Editor